|
業務類別
|
Biotechnology |
|
業務概覽
|
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH. |
| 公司地址
| 200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428 |
| 電話號碼
| +1 267 824-2827 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.madrigalpharma.com |
| 員工數量
| 915 |
| Ms. Rita Thakkar |
Senior Vice President and Chief Accounting Officer |
-- |
12/03/2026 |
| Ms. Carole Huntsman |
Executive Vice President and Chief Commercial Officer |
美元 540.31K |
28/04/2026 |
| Ms. Shannon T. Kelley |
Executive Vice President and Chief Legal Counsel |
美元 535.17K |
28/04/2026 |
| Dr. David Soergel, M.D. |
Executive Vice President and Chief Medical Officer |
美元 418.18K |
28/04/2026 |
| Ms. Mardi C. Dier |
Executive Vice President and Chief Financial Officer |
美元 566.04K |
28/04/2026 |
| Mr. William John Sibold |
Director, President and Chief Executive Officer |
美元 918.53K |
28/04/2026 |
|
|
| Dr. Paul A. Friedman,M.D. |
Director |
28/04/2026 |
| Dr. Jacqualyn A. Fouse, PhD |
Independent Director |
28/04/2026 |
| Dr. Rebecca A. Taub,M.D. |
Director |
28/04/2026 |
| Dr. Richard S. Levy,M.D. |
Independent Director |
28/04/2026 |
| Mr. Julian C. Baker |
Chairman of the Board |
28/04/2026 |
| Mr. James M. Daly |
Independent Director |
28/04/2026 |
| Dr. Raymond Cheong, M.D. |
Independent Director |
28/04/2026 |
| Mr. Daniel J. Brennan |
Independent Director |
28/04/2026 |
| Mr. William John Sibold |
Director, President and Chief Executive Officer |
28/04/2026 |
|
|
|
|
